LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

LLY

724.75

-2.78%↓

JNJ

153.19

-0.27%↓

ABBV

181.66

-1.71%↓

NVO

68.18

+0.09%↑

UNH

303.28

-5.72%↓

Начало・Списък с акции・Lisata Therapeutics

L
Lisata Therapeutics

Затворен

2.49 -4.23

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

2.25

Максимум

2.67

Ключови измерители
By Trading Economics
Служители	26

Дивиденти
By Dow Jones
Следващи печалби	11.08.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	470K 20M
Предишно отваряне	6.72
Предишно затваряне	2.49

Lisata Therapeutics Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2025 г., 23:25 ч. UTC

Горещи акции

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21.05.2025 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21.05.2025 г., 21:29 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Operations in Uruguay

21.05.2025 г., 21:01 ч. UTC

Значими двигатели на пазара

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21.05.2025 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion

21.05.2025 г., 23:49 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21.05.2025 г., 23:37 ч. UTC

Пазарно говорене

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21.05.2025 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21.05.2025 г., 23:32 ч. UTC

Придобивния, сливания и поглъщания

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21.05.2025 г., 23:32 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21.05.2025 г., 23:31 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21.05.2025 г., 23:30 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21.05.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21.05.2025 г., 23:28 ч. UTC

Печалби

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21.05.2025 г., 23:27 ч. UTC

Печалби

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21.05.2025 г., 23:26 ч. UTC

Печалби

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21.05.2025 г., 23:23 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21.05.2025 г., 23:22 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21.05.2025 г., 23:20 ч. UTC

Придобивния, сливания и поглъщания

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21.05.2025 г., 23:18 ч. UTC

Придобивния, сливания и поглъщания

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21.05.2025 г., 21:42 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21.05.2025 г., 21:14 ч. UTC

Придобивния, сливания и поглъщания

Millicom to Acquire Telefónica's Ops in Uruguay

21.05.2025 г., 21:07 ч. UTC

Топ новини

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21.05.2025 г., 21:06 ч. UTC

Придобивния, сливания и поглъщания

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

21.05.2025 г., 20:59 ч. UTC

Топ новини

Walmart to Cut 1,500 Jobs -- WSJ

21.05.2025 г., 20:52 ч. UTC

Печалби

Snowflake Stock Pops After Earnings Beat -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Lisata Therapeutics Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Lisata Therapeutics през последните 3 месеца.

Финанси

Относно Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.